Business Wire

Nordic Enterprises See SDN as Key to Network Agility, Working from Home

5.7.2021 11:00:00 EEST | Business Wire | Press release

Share

Enterprises in the Nordics are expanding their adoption of software-defined networking technology to become more agile and flexible while enabling employees to more easily work from home, according to a new report published today by Information Services Group (ISG) (Nasdaq: III), a leading global technology research and advisory firm.

The 2021 ISG Provider LensNetwork – Software Defined Solutions and Services Report for the Nordics finds enterprises in the region looking to SDN-related technologies and service providers to help them with challenges related to the flexibility, speed and collaboration they need to better serve their employees and their increasingly mobile customers.

“Nordic enterprises are looking to SDN and its service providers to increase their network agility, flexibility and competitiveness while enabling remote working and better business continuity,” said Jan Erik Aase, partner and global leader, ISG Provider Lens Research. “This new need for enterprise agility goes beyond the abilities of traditional networks in a constantly changing competitive environment.”

The report also sees enterprises in the region embracing SD-WAN to enable remote working. While WAN architecture at enterprises has created backhaul challenges, that architecture is evolving to support more connectivity choices. Vendors are enabling enterprises to use a variety of transport options actively or on standby.

In addition, Nordic enterprises are moving toward more automation and analytics. Enterprises are increasingly embracing the concept of the network as code, where changes in the network infrastructure can be handled through code changes. Service providers are leveraging automation tools and allowing visibility into the cloud, the data center, and the WAN. Nordic enterprises see SD-WAN as a way to drive automation, reduce reliance on network hardware and consolidate network functionality.

Nordic enterprises are also seeking end-to-end connectivity to analyze data at the edge, including data generated by Internet of Things (IoT) devices, the report says. Service providers and system integrators are exploring ways to bring new capabilities to Wi-Fi 6, long-term evolution (LTE) and fifth-generation (5G) networks. They are also looking to assist customers with large public 5G rollouts, with some spectrum potentially allocated for enterprises.

New SDN-related technologies will pave the way for the industrial IoT to scale up and for edge computing to grow further, the report adds. However, a more inclusive network ecosystem is needed for the cloud, which is evolving into a holistic web of network technologies that include components of SDN such as WAN, LAN and Wi-Fi 6 management.

The report also sees changes in network practices driven in part by the move in the Nordics to the cloud and to the software-as-a-service model. Enterprises there have been seeing more internet-based traffic, which has led them to consider new ways to look at connectivity. Enterprises are moving away from a conventional hub-and-spoke networking model and considering instead an any-to-any connectivity model that supports more cloud-oriented traffic patterns.

The 2021 ISG Provider LensNetwork – Software Defined Solutions and Services Report for the Nordics evaluates the capabilities of 55 providers across six quadrants: Managed (SD) WAN Services, SDN Transformation Services (Consulting and Implementation), SD-WAN Equipment and Service Suppliers (DIY), Technology and Service Suppliers (Core – 4G/5G), Edge Technology and Services, and Enterprise 5G Solutions.

The report names Orange Business Services as a leader in five quadrants and BT, Cisco, Deutsche Telekom, HCL, IBM, Tech Mahindra and Wipro as leaders in four. Ericsson, HPE Aruba and Nuage Networks are named leaders in three quadrants, and Infosys, TCS, Telenor, Telia, Verizon and VMware are named leaders in two. Citrix, Juniper Networks, Nokia Networks and Versa Networks are named leaders in one quadrant.

In addition, Tech Mahindra, Verizon and Wipro were named Rising Stars—companies with “promising portfolios” and “high future potential” by ISG’s definition—in two quadrants. GTT and Infosys were named Rising Stars in one quadrant each.

The 2021 ISG Provider LensNetwork – Software Defined Solutions and Services Report for the Nordics is available to subscribers or for one-time purchase on this webpage.

About ISG Provider Lens™ Research

The ISG Provider Lens™ Quadrant research series is the only service provider evaluation of its kind to combine empirical, data-driven research and market analysis with the real-world experience and observations of ISG's global advisory team. Enterprises will find a wealth of detailed data and market analysis to help guide their selection of appropriate sourcing partners, while ISG advisors use the reports to validate their own market knowledge and make recommendations to ISG's enterprise clients. The research currently covers providers offering their services globally, across Europe, as well as in the U.S., Germany, Switzerland, the U.K., France, the Nordics, Brazil and Australia/New Zealand, with additional markets to be added in the future. For more information about ISG Provider Lens research, please visit this webpage.

A companion research series, the ISG Provider Lens Archetype reports, offer a first-of-its-kind evaluation of providers from the perspective of specific buyer types.

About ISG

ISG (Information Services Group) (Nasdaq: III) is a leading global technology research and advisory firm. A trusted business partner to more than 700 clients, including more than 75 of the world’s top 100 enterprises, ISG is committed to helping corporations, public sector organizations, and service and technology providers achieve operational excellence and faster growth. The firm specializes in digital transformation services, including automation, cloud and data analytics; sourcing advisory; managed governance and risk services; network carrier services; strategy and operations design; change management; market intelligence and technology research and analysis. Founded in 2006, and based in Stamford, Conn., ISG employs more than 1,300 digital-ready professionals operating in more than 20 countries—a global team known for its innovative thinking, market influence, deep industry and technology expertise, and world-class research and analytical capabilities based on the industry’s most comprehensive marketplace data. For more information, visit www.isg-one.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Will Thoretz, ISG
+1 203 517 3119
will.thoretz@isg-one.com

Erik Arvidson, Matter Communications for ISG
+1 617 755 2985
isg@matternow.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye